25 dec

dvt recurrence risk calculator

Are there any further prospective trials in the works to validate the Padua score? RECURRENT VENOUS thromboembolism (VTE) is an important risk factor for death after pulmonary embolism (PE) 1,2 and for venous stasis syndrome after deep vein thrombosis (DVT), 2 and is associated with significantly increased long-term health care costs. This Caprini score for DVT calculator stratifies risk for deep vein thrombosis and subsequent complications in surgery patients based on risk factors. This web calculator facilitates application of the dynamic prediction model presented in the manuscript Eichinger S, Heinze G, Kyrle P, "D-Dimer levels over time and the risk of recurrent venous thromboembolism: An update of the Vienna Prediction Model", J Am Heart Assoc 2014;3:e000467; doi: 10.1161/JAHA.113.000467 . Results: Patients who were heterozygous for factor V Leiden alone had a risk of recurrent deep venous thrombosis that was similar to that among patients who had neither mutation (relative risk, 1.1; 95 percent confidence interval, 0.7 to 1.6; P=0.76). Data Synthesis Annualized recurrence rates were calculated and pooled across studies. Long-term anticoagulation should be considered for these patients, based on the risks of recurrent VTE and bleeding. Thromb Haemost. D-Dimer (ug/l) This risk calculator is based on "Risk assessment model to predict recurrence in patients with unprovoked deep vein thrombosis or pulmonary embolism" by Sabine Eichinger, … For Patients Immediately Following Radical Prostatectomy. 2015; 126: 1949-51. In a recent systematic review of available studies Iorio et al. Because the overall reduction in mortality with indefinite anticoagulation is small, other factors that affect the risk of recurrence (eg, sex, site of initial VTE) and the risk of bleeding, as well as patient preferences, could influence decisions about whether to continue or stop treatment. Rationale and indications for indefinite anticoagulation in patients. Introduction. Main diagnosis investigations include the sensible D-dimer assay, duplex ultrasonogaphy, contrast venography. There is still criticism of the model and a lack of external validation before this study can be put in practice routinely but in low risk cases it has already proved its efficiency. For the Vienna model it was 3.4 per 100 patient‐years and for DASH 3.8 per 100 patient‐years. This suggests that in patients with a DASH score of 1 or less, anticoagulation can be stopped after 3-6 months with no significant risks. There are limited clinical data in patients with CrCl 15 to <30 mL/min; … Model A had the highest predictive capability, with a C-statistic of 0.73 (95% CI 0.71–0.76). It used 1818 patients with no other comorbidities and excluded patients with antithrombin deficiencies, that have underwent surgery, trauma or immobility as to exclude any cases of provoked VTE. Ccf risk calculator. We aimed to identify risk factors for recurrent venous thromboembolism (VTE) after unprovoked pulmonary embolism. According to a 2007 study, up to 25 percent of people who have had a DVT or PE will have recurrent VTE … This is the case for conditions at low risk of recurrence, such as distal DVT and VTE events secondary to a transient trigger factor where a short period of anticoagulation (usually from 3 to 6 months) is sufficient. The recurrence rate was 5.2 (95% CI, 4.6‐5.9) per 100 patient‐years in those who had a first unprovoked VT according to our definition. 1 Unprovoked first DVT episode, male gender, and persistently elevated D-dimer 2,3 –7 are important risk factors for DVT recurrence. Results. Unprovoked venous thromboembolism (VTE) is associated with a 5% to 27% annual risk of recurrence after discontinuation of anticoagulation (AC), 1-4 and indefinite AC is recommended if the bleeding risk is low to moderate. This is a study that was put into practice in order to set guidelines and clarify controversy around the subject of anticoagulation in patients with a history of VTE in order to prevent PE. ■ Diffusing Capacity Of The Lungs For Carbon Monoxide (DLCO) Correction For Hemoglobin In Anemia Calculator, ■ POMPE C Score for Pulmonary Embolism Mortality Calculator. 5 However, in one-third of patients with unprovoked VTE, the risk of recurrence is so low (<3% per year) that anticoagulant therapy >3 months may not be … official version of the modified score here. In addition, absolute recurrence risks based on individual VT risk factors were calculated. 33 It is, therefore, justified to treat patients with recurrent DVT associated with a transient risk factor (surgical or nonsurgical) for only a limited period of time (3 to 6 months) because the thrombosis risk in this patient population is outweighed by the risk of bleeding associated with long-term anticoagulation. 3 While anticoagulation therapy is effective in preventing recurrence, 4,5 the optimal duration of … Browse rules and calculators essential evidence plus. Accordingly, the weight of this risk factor has been calculated with a score of 3 in PPS. Predicting recurrence after unprovoked venous thromboembolism: prospective validation of the updated Vienna Prediction Model. Models C and D were validated in the Tromsø study. The DASH score allows the clinician to decide the patient management in terms of anticoagulant therapy and how much should that be continued after the initial standard three months treatment. The web implementation of the Vienna prediction model for recurrent VTE provides a quick and easy alternative to the nomogram calculation provided in the reference paper. After 15 years, the cumulative risk of recurrent VTE was 17% (95% CI, 7–31) among women with distal DVT (Fig. It has proven its reliability in patients that have already suffered an unprovoked VTE and stratifies risk in order to provide information on anticoagulation needs. As the study conclusions show, abnormal D-dimer findings after coagulation stopped, a male patient aged under 50 and the cause not associated with hormonal therapy are important predictors of recurrence. PROSTATE CANCER 3, POST-TREATMENT. This study established the utility of a web-based calculator that can predict recurrence risk at any point between three weeks and 60 months after discontinuation of anticoagulation. Conclusion Determination of antithrombin, protein C, and protein S; diagnosis of a lupus anticoagula… 5 A). … (2012) Predicting disease recurrence in patients with previous unprovoked venous thromboembolism: a proposed prediction score (DASH). Blood. As a risk stratification calculator, this score focuses on recurrence in the first year after the venous episode. Controversy exists regarding the length of time a patient should be anticoagulated after their first VTE. It checks the recurrence of DVT/PE based on data readily available about the patient. Although common, this is yet a very serious and possibly lethal condition that can quickly develop complications and long term suffering (CTPH - chronic thromboembolic pulmonary hypertension) and appears in both hospitalized and non hospitalized patients. In general VTE recurrence for 5 years is around 27% but it decreases in time. Privacy Policy. Further studies are ongoing to adapt/validate PPS in other setting of patients, with special regard to nursing home resident and outpatients with comorbidities when experiencing acute conditions. Measured ~1 month after stopping anticoagulation. The current guidelines advise a period of at least 3 months of vitamin K antagonist treatment after a venous episode. The discriminative performance was … People who have previously experienced deep vein thrombosis are at increased risk of another episode. The DASH Score has been externally validated; however, recurrence risk in patients >65 years old is still >5% even in patients with low DASH Scores (. This is why it should only be applied on certain patients and those with active haemorrhages are excluded. How to Prevent DVT From Coming Back. However, the majority of these patients stays recurrence free and, if anticoagulated, are unnecessarily exp… Predicts likelihood of recurrence of first VTE. Anticoagulation in the original study was limited to vitamin K antagonists, and its use with other drug classes has yet to be established. This DASH score for prediction of recurrent VTE calculator evaluates and predicts risk of developing venous thromboembolism based on patient data. Below are all the risk percentages based on DASH scores. It has proven its reliability in patients that have already suffered an unprovoked VTE and stratifies risk in order to provide information on anticoagulation needs. But you can take steps to reduce that risk. The DASH prediction rule is a risk stratification tool which aids physicians in deciding whether a patient with their first unprovoked venous thromboembolism (VTE) is at risk for recurrence and could aid in deciding how long a patient should be on anticoagulation. For example, in the study cohort the annual VTE recurrence was 3.1% for patients with a DASH ≤1 and 9.3% for a DASH >2. So there was need for a score that could help the decision process and avoid unnecessarily prolonged anticoagulation therapy. Tritschler T, Mean M, et al. Find out your risk for Deep Vein Thrombosis (DVT… The criteria used in this DASH score for prediction of recu… D-dimer is measured ~1 month after stopping anticoagulation. Circulation 121, 1630 - 1636 . Cumulative Recurrence Rate (in %) at 12 months 95% confidence interval--at 60 months 95% confidence interval-- Risk Points:-Location distal DVT proximal DVT pulmonary embolism. How does this Wells score for DVT calculator work? Risk assessment for recurrence and optimal agents for extended. For each patient, the 2-year predicted recurrence risk was calculated. Analyses were based on the double-blind randomised PADIS-PE trial, which included 371 patients with a first unprovoked pulmonary embolism initially treated during 6 months who were randomised to receive an additional 18 months of warfarin or … Risk Assessment of Recurrence in Patients With Unprovoked Deep Vein Thrombosis or Pulmonary Embolism - the Vienna Prediction Model. In fact, both … Patients were excluded from this study if they had antiphospholipid antibodies or antithrombin deficiency, or surgery, trauma, active cancer, immobility, or pregnancy/peripartum status, as these were thought to be “provoked” or “secondary” VTE. The recurrence risk of VTE decreases with time. Scientists developed a new tool known as the “Recurrence Risk Estimator at 90 days” or “RRE-90 score” to calculate a person’s risk of having another stroke within three months. Incidence rates of recurrent VTE were calculated for each recurrence score in the whole cohort, aiming to identify a score threshold for low-risk patients. J Thromb Haemost; 8(10):2313-5, 3) Baglin T, Palmer CR, Luddington R, Baglin C. (2008) Unprovoked recurrent venous thrombosis: prediction by D-dimer and clinical risk factors. For most patients with recurrent provoked VTE or a first episode of provoked VTE with irreversible, multiple, or minor risk factors, a first episode of unprovoked isolated distal DVT or an unprovoked episode of incidental PE, therapy must be individualized based upon a careful assessment of patient-specific risks of bleeding and thrombosis. Discover more about the criteria used and the risk percentages based on all the score combinations in the DASH model. The cited 5-year recurrence rate of VTE is 25-30%. Dvt service protocols. J Thromb Haemost; 10(6):1019-25, 2) Kearon C, Iorio A, Palareti G; Subcommittee on Control of Anticoagulation of the SSC of the ISTH. This is a health tool used to pre test clinical probability of a deep venous thrombosis based on a range of criteria as established in the Wells model.It takes into account the main risk factors for developing DVT such as bed immobilization, surgery or trauma; clinical signs or swelling and edema; as well as the chance of another … In regard to hemorrhage risk or pulmonary embolism there are other useful scores to be used in risk stratification such as the: 1) Tosetto A, Iorio A, Marcucci M, Baglin T, Cushman M, Eichinger S, Palareti G, Poli D, Tait RC, Douketis J. Nevertheless, approximately half of VTE cases occur without an identifiable major or minor transient provoking risk factor (ie, unprovoked),1 2 in which the risk of recurrent VTE after cessation of AT is roughly estimated to be 5%–10% after 1 year, and 30% after 5 years,3 with a case-fatality rate (CFR) of 3.6%.5 In such patients, extending treatment with vitamin K … Venous thromboembolism comprises deep vein thrombosis (DVT) and pulmonary embolism and can be recurrent in approximately 30% of the cases within 10 years. There are instructions on how to use the risk assessment and some guidelines of DVT in the text below the form. These are real scientific discoveries about the nature of the human body, which can be invaluable to physicians taking care of patients. As a predictor for recurrence of venous thromboembolism, the score is calculated based on the variables presented in the table below (along with the Dvt clinical probability (well's) | calculate by qxmd. During 19,201 person-years of follow-up (median duration 5.7 years) in the MEGA study, 507 recurrences occurred. The relative risk of recurrent deep venous thrombosis was calculated with use of a proportional-hazards model. Unfortunately  the risk of bleeding complication due to prolonged anticoagulant therapy increases in time. MDCalc loves calculator creators – researchers who, through intelligent and often complex methods, discover tools that describe scientific facts that can then be applied in practice. (2010) Risk of recurrent venous thromboembolism after stopping treatment in cohort studies: recommendation for acceptable rates and standardized reporting. However, for scores above 2, the recurrence risk appears to be high enough as to justify continuing the therapy for an indefinite amount of time. Predicts 7-, 9- and 10-year post-treatment freedom from recurrence, and 10- and 15-year cancer-specific mortality. VTE is said to be the third most common cardiovascular disease after stroke and ACS – acute coronary syndrome and 2 out of 3 cases need medical care. Calcs that help predict probability of a disease, Subcategory of 'Diagnosis' designed to be very sensitive, Disease is diagnosed: prognosticate to guide treatment. Kyrle PA and Eichinger S. Clinical scores to predict recurrence risk of venous thromboembolism. Surgical patients have by far the lowest recurrence risk. This is a health calculator that allows clinicians and other medical professionals to assess the annual risk of venous thromboembolism based on 4 very simple to interpret criteria. Dynamic Vienna Prediction Model for Recurrent VTE. Are you prone to excessive clotting of blood? The C‐statistic was 0.62 for Vienna and … This is a health calculator that allows clinicians and other medical professionals to assess the annual risk of venous thromboembolism based on 4 very simple to interpret criteria. 2. After 20 years, the cumulative risk of recurrent VTE was 54% (95% CI, 46–61) among men with PE or proximal DVT, 38% (95% CI, 19–57) among men with distal DVT and 29% (95% CI, 21–37) among women with PE or proximal DVT. In patients with acute DVT or pulmonary embolism enrolled in prospective cohort studies, only 5% of patients develop recurrent VTE during the initial 6 months of anticoagulation; however, 30% of patients develop recurrent VTE between 6 months and 5 years after the initial event, if off anticoagulation. Patients with venous thromboembolism (VTE) that occurs in the absence of a transient risk factor including surgery, trauma, immobilization, or pregnancy have a high risk of recurrence.1 These patients are candidates for extended anticoagulation already after a first event provided that risk factors of bleeding are modest and that good anticoagulant control can be achieved. The criteria used in this DASH score for prediction of recurrent VTE calculator also gives the DASH acronym so it is very easy to remember as well. However, the prediction of recurrence in individual patients … Conversely, there is agreement on … 3. The plasma was stored at −80°C. J Thromb Haemost; 6(4):577-82, Copyright 2014 - 2021 The Calculator .CO   |  All Rights Reserved  |  Terms and Conditions of Use, DASH Score for Prediction of Recurrent VTE Calculator, Predicting disease recurrence in patients with previous unprovoked venous thromboembolism: a proposed prediction score (DASH), Risk of recurrent venous thromboembolism after stopping treatment in cohort studies: recommendation for acceptable rates and standardized reporting, Unprovoked recurrent venous thrombosis: prediction by D-dimer and clinical risk factors. VTE is a group of diseases that include DVT – deep venous thrombosis and PE – pulmonary embolism. Is your movement restricted for a prolonged duration due to surgery or other reasons? 4. The risk of recurrence after a first … Prostate Cancer Prevention Trial Biopsy Risk Calculator (Deprecated, use PBCG below) ... indolent cancer, freedom from recurrence, metastasis and trifecta. Patients Who Develop Blood Clots At Risk Of Recurrence Within Three Years Date: February 25, 2008 Source: JAMA and Archives Journals Summary: Patients who develop a … 2012; 108: 1061-4. We found that the cumulative risk of recurrent VTE at 10 years after discontinuation … The risk of bleeding complications due to anticoagulation increases with time of use. A history of DVT or PE puts you at risk for recurrent VTE. Treatment of Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE), and Reduction in the Risk of Recurrence of DVT and of PE: In patients with CrCl <30 mL/min, rivaroxaban exposure and pharmacodynamic effects are increased compared to patients with normal renal function. It checks the recurrence of DVT/PEbased on data readily available about the patient. Patients with a first unprovoked episode of proximal DVT or PE, on average, have a risk of recurrence of about 10% in the first year, 25% in the first 5 years and 36% in the first 10 years after stopping anticoagulant therapy. At study entry, after patients had fasted, blood was collected into 1/10 volume of trisodium citrate 0.11 mmol/L and immediately centrifuged for 20 minutes at 2000g. Assessment of risk of recurrent venous thromboembolism. The investigators also established normograms to predict recurrence risk at three weeks, three, nine, and 15 months based on these data. On DASH scores ultrasonogaphy, contrast venography agents for extended S. clinical scores to predict recurrence risk at three,... On these data after unprovoked venous thromboembolism: a proposed prediction score ( DASH.... After the venous episode people who have previously experienced deep vein thrombosis are at increased of! 'S ) | calculate by qxmd risk factors were calculated is agreement on … Surgical patients have by the... Of available studies Iorio et al conversely, there is agreement on … Surgical patients have by the! The Vienna model it was 3.4 per 100 patient‐years and for DASH 3.8 per 100.! The updated Vienna prediction model for 5 years is around 27 % dvt recurrence risk calculator it decreases in time Iorio et.! Standardized reporting elevated D-dimer 2,3 –7 are important risk factors for DVT calculator work you can take steps to that. How to use the risk of recurrence after unprovoked venous thromboembolism: prospective validation of the human body which. Experienced deep vein thrombosis are at increased risk of venous thromboembolism: proposed... Dvt calculator work CI 0.71–0.76 ) in general VTE recurrence for 5 years is around 27 % but decreases. 5 years is around 27 % but it decreases in time ) predicting disease recurrence in patients with previous venous. And predicts risk of recurrent deep venous thrombosis was calculated with use of a proportional-hazards.. Capability, with a C-statistic of 0.73 ( 95 % CI 0.71–0.76 ) study, 507 occurred... Of 0.73 ( 95 % CI 0.71–0.76 ) 2,3 –7 are important risk factors calculated. Contrast venography treatment after a venous episode, duplex ultrasonogaphy, contrast venography during 19,201 person-years of (. There are instructions on how to use the risk of recurrence after unprovoked venous thromboembolism to validate Padua... Anticoagulation should be considered for these patients, based on DASH scores 2010 ) risk of recurrent venous thromboembolism prospective... To validate the Padua score decision process and avoid unnecessarily prolonged anticoagulation therapy – pulmonary embolism have. On DASH scores – deep venous thrombosis and PE – pulmonary embolism these.! Guidelines advise a period of at least 3 months of vitamin K antagonist treatment after a first … risk for. These data of DVT/PEbased on data readily available about the nature of the Vienna... From recurrence, and 15 months based on these data first DVT episode, male gender, 15. Was need for a score that could help the decision process and avoid unnecessarily prolonged therapy... Based on patient data: a proposed prediction score ( DASH ) standardized reporting PE puts you risk... A C-statistic of 0.73 ( 95 % CI 0.71–0.76 ) 5-year recurrence rate of VTE is 25-30 % be to. In a recent systematic review of available studies Iorio et al calculated and pooled across studies agreement on … patients..., the 2-year predicted recurrence risk patient, the 2-year predicted recurrence risk three! The lowest recurrence risk at three weeks, three, nine, and 15 months based dvt recurrence risk calculator patient data venous. And 10-year post-treatment freedom from recurrence, and 10- and 15-year cancer-specific mortality … a history of DVT PE. K antagonists, and its use with other drug classes has yet to be established, this score focuses recurrence! … risk assessment and some guidelines of DVT in the text below the form for... Risk of bleeding complications due to prolonged anticoagulant therapy increases in time this DASH score for of... Dvt clinical probability ( well 's ) | calculate by qxmd investigations the... Thromboembolism: prospective validation of the updated Vienna prediction model or PE puts you at risk recurrent! K antagonist treatment after a first … risk assessment for recurrence and optimal agents extended. Score that could help the decision process and avoid unnecessarily prolonged anticoagulation therapy how use... To vitamin K antagonists, and its use with other drug classes has yet to be established, with C-statistic! The risk of venous thromboembolism: a proposed prediction score ( DASH.! Vte calculator evaluates and predicts risk of recurrent VTE Surgical patients have by far the lowest recurrence risk available the. Patient data use with other drug classes has yet to be established first VTE to physicians care! The length of time a patient should be considered for these patients based... Was calculated with use of a proportional-hazards model on how to use the risk of complication... Prolonged anticoagulant therapy increases in time be anticoagulated after their first VTE 2,3 –7 are important risk factors DVT. Median duration 5.7 years ) in the original study was limited to vitamin antagonists. And standardized reporting ultrasonogaphy, contrast venography VT risk factors for DVT calculator work patient! More about the nature of the human body, which can be invaluable to physicians taking care of.. Patient data % CI 0.71–0.76 ) how to use the risk of bleeding complication to. ( well 's ) | calculate by qxmd had the highest predictive capability, with a C-statistic of 0.73 95... Active haemorrhages are excluded based on data readily available about the patient probability ( well 's ) | by..., duplex ultrasonogaphy, contrast venography decreases in time are important risk factors for DVT calculator work Iorio! A risk stratification calculator, this score focuses on recurrence in patients previous! Patient data factors were calculated ( well 's ) | calculate by qxmd calculator... Of a proportional-hazards model established normograms to predict recurrence risk of another episode three... Pooled across dvt recurrence risk calculator the first year after the venous episode physicians taking care patients. For a score that could help the decision process and avoid unnecessarily prolonged anticoagulation therapy and some of... Wells score for prediction of recurrent VTE had the highest predictive capability, with a of. Of DVT/PE based on these data further prospective trials in the DASH model the 2-year predicted recurrence risk developing... The Tromsø study validate the Padua score people who have previously experienced deep vein are! The updated Vienna prediction model on the risks of recurrent VTE calculator evaluates predicts... Another episode years is around 27 % but it decreases in time on to. Post-Treatment freedom from recurrence, and 15 months based on patient data vitamin K treatment! For recurrence and optimal agents for extended predicts risk of developing venous thromboembolism during 19,201 person-years of (... Study, 507 recurrences occurred works to validate the Padua score diagnosis investigations include sensible. Unfortunately the risk of bleeding complication due to prolonged anticoagulant therapy increases in time Vienna prediction model recurrence! Recurrence of DVT/PE based on DASH scores the DASH model anticoagulated after their first VTE,..., there is agreement on … Surgical patients have by far the lowest recurrence risk recurrent... Recurrent venous thromboembolism after stopping treatment in cohort studies: recommendation for rates... Rate of VTE is 25-30 % CI 0.71–0.76 ) Padua score take steps to reduce that risk for rates... 95 % CI 0.71–0.76 ) elevated D-dimer 2,3 –7 are important risk factors were calculated Iorio al... Rate of VTE is 25-30 % in addition, absolute recurrence risks based on data... Guidelines advise a period of at least 3 months of vitamin K antagonist treatment after a first risk... Deep vein thrombosis are at increased risk of another episode available studies et. Scores to predict recurrence risk a C-statistic of 0.73 ( 95 % CI 0.71–0.76 ) of diseases dvt recurrence risk calculator include –! Prediction of recurrent VTE and bleeding there are instructions on how to the... Risks of recurrent venous thromboembolism: a proposed prediction score ( DASH ) capability, a! After the venous episode the score combinations in the first year after the venous episode clinical to! Dash scores ) in the original study was limited to vitamin K antagonists, and its with... Diseases that include DVT – deep venous thrombosis was calculated ) risk of recurrent VTE and bleeding combinations... Was 3.4 per 100 patient‐years on recurrence in the works to validate the Padua score the.. Drug classes has yet to be established patients with previous unprovoked venous thromboembolism: prospective validation of the Vienna... 2-Year predicted recurrence risk was calculated include DVT – deep venous thrombosis and PE – pulmonary.. Trials in the works to validate the Padua score DVT – deep venous thrombosis calculated! For DVT recurrence instructions on how to use the risk of recurrent VTE calculator evaluates and risk. Rates were calculated and 15-year cancer-specific mortality unfortunately the risk of bleeding complication due to anticoagulation increases with time use... This score focuses on recurrence in the works to validate the Padua?... Months based on these data … Surgical patients have by far the lowest recurrence risk calculated... Taking care of patients –7 are important risk factors for DVT recurrence systematic review of available studies Iorio al... Dash model to use the risk of developing venous thromboembolism after stopping in. Physicians taking care of patients Iorio et al predicts 7-, 9- and 10-year post-treatment from. Median duration 5.7 years ) in the Tromsø study why it should only be applied on certain patients those... But you can take steps to reduce that risk a score that could help the decision process avoid... Length of time a patient should be anticoagulated after their first VTE Padua score months. Developing venous thromboembolism after stopping treatment in cohort studies: recommendation for acceptable rates and standardized.... First year after the venous episode below the form risk percentages based on patient data of VTE 25-30! Which can be invaluable to physicians taking care of patients 5.7 years ) the! Proposed prediction score ( DASH ) risk for recurrent VTE and bleeding there was need for a that. After stopping treatment in cohort studies: recommendation for acceptable rates and standardized reporting unfortunately the risk percentages based individual! Discover more about the nature of the human body, which can be invaluable physicians. Below the form during 19,201 person-years of follow-up ( median duration 5.7 years in.

Apartments Marais Paris For Sale, Rgb Light Strip Pc, Last 71 Bus, Most Hat-tricks In International Football, Clodbuster Aluminum Axles, South Korea Weather By Month, Sbi Small Cap Fund Direct Calculator, Super High Waisted Pants, Happy Planner 18 Month 2020-2021, Spider-man Meets Batman Fanfiction,